Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Abciximab in High Risk Coronary Angioplasty
NCT00269893Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 1991
- Primary completion
- Nov 1992
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of abciximab in unstable angina and myocardial infarction (MI) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Death, Myocardial Infarction, or Recurrent Ischemic Event Requiring Urgent Intervention at 30 days. Started Nov 1991; status: completed.
02
Drugs
abciximab
03
Conditions
unstable anginamyocardial infarction (MI)
Beyond the preview
Go deeper on NCT00269893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269893.